Tech Company Financing Transactions

Edgewise Therapeutics Funding Round

Viking Global Investors, Cormorant Asset Management and CureDuchenne Ventures participated in a $95 million Series C funding round for Edgewise Therapeutics. The round closed on 12/10/2020.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

3415 Colorado Ave.
Boulder, CO 80304
USA

Phone

(303) 735-8373

Website

www.edgewisetx.com

Email Address

[email protected]

Overview

Edgewise Therapeutics is a new company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Kevin Koch

        

Chief Financial Officer

Michael Carruthers

        

Chief Medical Officer

Kirsten Gruis

        

Chief Scientific Officer

Alan Russell

        

Vice President

Abby Bronson

        

VP - Bus. Development

Behrad Derakhshan

        

VP - General Counsel

John Moore

        

VP - Regulatory Affairs

Nicole Kilburn

        

Browse more venture capital transactions:

Prev: 12/10/2020: Squire Technologies venture capital transaction
Next: 12/10/2020: Arthur venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary